cover
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
japr.editor@gmail.com
Editorial Address
Plot No. 105/42, Opposite electricity sub station, Changorabhata, Raipur (Chhattisgarh), India 492001
Location
,
INDONESIA
Journal of Applied Pharmaceutical Research
Published by Creative Pharma Assent
ISSN : -     EISSN : 23480335     DOI : 10.18231
Core Subject : Health,
Journal of Applied Pharmaceutical Research (JOAPR) is an official publication of Creative Pharma Assent (CPA). It is an open access, peer review online international journal. JOAPR is primarily focused on multiple discipline of pharmaceutical sciences (Pharmaceutics, Pharmaceutical Technology, Biopharmaceutics, Cosmetic Technology, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Herbal drugs/ formulations, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest) which publish quarterly. JOAPR also includes evaluation of pharmaceutical excipients & their practical application to research & industry based efforts. The aim of the scientific journal, JOAPR is to present a wide area for the current researchers to share their noble works and ideas in terms of the research papers, review articles and short communications. JOAPR only publish the original research works with a definite innovation and novelty after thorough reviewing. The paper must have a suitable and proper scientific background.
Arjuna Subject : -
Articles 1 Documents
Search results for , issue "Vol. 7 No. 4 (2019)" : 1 Documents clear
Synthesis and characterization of anti-infective agents Sharma, Monika; Sharma, Sonu; Arora, Neha; Sharma, Shreya; Matta, Yogesh; Sharma, Sharad
Journal of Applied Pharmaceutical Research Vol. 7 No. 4 (2019)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1018.787 KB) | DOI: 10.18231/j.joapr.2019.v.7.i.4.002

Abstract

Antifungal chemotherapy depends on bio-chemical alterations between fungi and mammals. Unlike bacteria, which are prokaryotes, both fungi and mammals are eukaryotes and the biochemical differences between them are not significant. However, there are some differences (in structure & metabolism) and focus is on these differences that act as targets for development of antifungal agents. The current recommendation of standard TB chemotherapy, called Directly observed treatment (DOTS) is a therapy of six month in which consists an first two-month phase of cure with four first-line drugs i.e. isoniazid, Rifampicin, Pyrazinamide, and Ethambutol. In this study large number of compounds is manufactured in which Most of the tested molecules showed maximum bacteriological growth inhibition at tested concentration. The combinations (7e, 7g, 7h, 7i and 7u) exhibited bacteriological growth inhibition at concentration of less than 40.0μg/ml against both microorganisms. Compounds (7o) showed growth of inhibition at 2.5μg/ml against both microorganisms. Additional challenging for all compounds at lower concentrations is mandatory to compare their activity through standard Streptomycin at its MIC to get exact MIC the manufactured combinations. Thus it can be concluded that designed 1, 3, 4-oxadiazole derivatives (7a-v) were manufactured successfully using planned synthetic outline. After manufactured the molecules were characterized using spectroscopy analysis and tested for the biological activity. All combinations showed anti-bacterial action at tested concentration against both gram positive and gram negative organisms and one of the compound 7o showed activity at concentration <2.5 μg/ml. Thus, these 1, 3, 4-oxadiazole results can then act as a potential principal for drug discovery of novel anti-infective agents.

Page 1 of 1 | Total Record : 1


Filter by Year

2019 2019


Filter By Issues
All Issue Vol. 13 No. 4 (2025) Vol. 13 No. 3 (2025) Vol. 13 No. 2 (2025) Vol. 13 No. 1 (2025) Vol. 12 No. 6 (2024) Vol. 12 No. 5 (2024) Vol. 12 No. 4 (2024) Vol. 12 No. 3 (2024) Vol. 12 No. 2 (2024) Vol. 12 No. 1 (2024) Vol. 11 No. 5 (2023) Vol. 11 No. 4 (2023) Vol. 11 No. 3 (2023) Vol. 11 No. 2 (2023) Vol. 11 No. 1 (2023) Vol. 10 No. 4 (2022) Vol. 10 No. 3 (2022) Vol. 10 No. 2 (2022) Vol. 10 No. 1 (2022) Vol. 9 No. 4 (2021) Vol. 9 No. 3 (2021) Vol. 9 No. 2 (2021) Vol. 9 No. 1 (2021) Vol. 8 No. 4 (2020) Vol. 8 No. 3 (2020) Vol. 8 No. 2 (2020) Vol. 8 No. 1 (2020) Vol. 7 No. 4 (2019) Vol 7 No 3 (2019) Vol. 7 No. 3 (2019) Vol 7 No 2 (2019) Vol. 7 No. 2 (2019) Vol 7 No 1 (2019) Vol. 7 No. 1 (2019) Vol 6 No 4 (2018) Vol. 6 No. 4 (2018) Vol 6 No 3 (2018) Vol. 6 No. 3 (2018) Vol 6 No 2 (2018) Vol. 6 No. 2 (2018) Vol 6 No 1 (2018) Vol. 6 No. 1 (2018) Vol. 5 No. 4 (2017) Vol 5 No 4 (2017) Vol 5 No 3 (2017) Vol. 5 No. 3 (2017) Vol. 5 No. 2 (2017) Vol 5 No 2 (2017) Vol. 5 No. 1 (2017) Vol 5 No 1 (2017) Vol 4 No 4 (2016) Vol. 4 No. 4 (2016) Vol. 4 No. 3 (2016) Vol 4 No 3 (2016) Vol. 4 No. 2 (2016) Vol 4 No 2 (2016) Vol 4 No 1 (2016) Vol. 4 No. 1 (2016) Vol 3 No 4 (2015) Vol. 3 No. 4 (2015) Vol 3 No 3 (2015) Vol. 3 No. 3 (2015) Vol. 3 No. 2 (2015) Vol 3 No 2 (2015) Vol 3 No 1 (2015) Vol. 3 No. 1 (2015) Vol 2 No 4 (2014) Vol. 2 No. 4 (2014) Vol. 2 No. 3 (2014) Vol 2 No 3 (2014) Vol. 2 No. 2 (2014) Vol 2 No 2 (2014) Vol 2 No 1 (2014) Vol. 2 No. 1 (2014) Vol. 1 No. 1 (2013) Vol 1 No 1 (2013) More Issue